SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc., (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that it appointed
Michele L. Yelmene to the new position of vice president of regulatory
affairs. Ms. Yelmene will direct the execution of the Company's ongoing
global regulatory strategy and be responsible for all regulatory
submissions for the Company's product candidates.
"Michele brings tremendous experience in regulatory affairs management
and product submissions for a range of highly successful pharmaceutical and
biological therapies," said Evan M. Levine, ADVENTRX chief executive
officer. "Her role will be instrumental as we advance the development of
CoFactor(R) (ANX-510) and vinorelbine emulsion (ANX-530), and, pending
appropriate approvals, anticipate moving additional products into the
clinic this year."
Michele Yelmene brings over 25 years of operational and project
management, clinical and scientific research and regulatory affairs
experience in the biotechnology and pharmaceutical industries. From
2002-2006, she was Executive Director, Clinical and Regulatory Affairs and
Corporate Secretary for Perlan Therapeutics, a privately-held company
focused on development of recombinant protein-based drugs. From 1998-2002,
Ms. Yelmene was Director in Biomedical Operations for Genzyme Corporation
and from 1996-1998 she was Manager of Medical and Regulatory Affairs for
Mallinckrodt. During her career, Ms. Yelmene was responsible for clinical
development, preparation, and presentation of 14 FDA-approved products and
over 25 investigational new drug applications (INDs) for both
pharmaceutical and biologics-based therapies in the areas of viral
infections, respiratory, CNS, metabolic and endocrine diseases, and
lysosomal storage disorders. She has participated in meetings with the FDA
at all phases (pre-IND through Advisory Committee) of clinical development.
Ms. Yelmene is a member of the Regulatory Affairs Professional Society,
Drug Information Association and Co-Chair of the FDA Committee at BIOCOM in
San Diego. She received a BS degree in Biology and BA degree in English
Writing, both from Rider University.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems, such as drug metabolism and
bioavailability, excessive toxicity and treatment resistance. The Company's
lead product candidate, ANX-510 (CoFactor), is in Phase III and Phase IIb
clinical trials for the treatment of metastatic colorectal cancer, as well
as in a Phase II clinical trial for the treatment of advanced breast
cancer. More information can be found on the Company's web site at
http://www.adventrx.com.
Forward-Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
that, if they do not materialize or prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The potential
risks and uncertainties that could cause actual results to differ
materially include, but are not limited to: successfully educating new
executives and integrating new executives with existing executives and
management; uncertainties inherent in the drug development process; the
timing and success of clinical trials; the validity of research results;
the receipt of necessary approvals from the FDA and other regulatory
agencies; and other risks and uncertainties more fully described in
ADVENTRX's press releases and public filings with the Securities and
Exchange Commission. ADVENTRX's public filings with the Securities and
Exchange Commission are available at http://www.sec.gov. ADVENTRX does not intend
to update any forward-looking statement, including as set forth in this
press release, to reflect events or circumstances arising after the date on
which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
http://www.prnewswire.com/comp/920134.html /
CONTACT:
Ioana C. Hone of ADVENTRX Pharmaceuticals,
Inc., +1-858-552-0866; or Amy Martini of WeissComm Partners,
+1-212-301-7223, for ADVENTRX Pharmaceuticals, Inc.
|
